14:41 , Mar 4, 2019 |  BC Extra  |  Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
19:32 , Dec 14, 2018 |  BC Week In Review  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was...
23:34 , Dec 13, 2018 |  BC Extra  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Wednesday that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
00:04 , Sep 22, 2017 |  BC Extra  |  Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
15:07 , Sep 1, 2017 |  BC Week In Review  |  Company News

AGTC and the FFB partner to advance opthalmic research

Applied Genetics Technology Corp. (NASDAQ:AGTC) provided The Foundation Fighting Blindness Inc. (Columbia, Md.) an undisclosed grant which the foundation will use to fund its My Retina Tracker registry as well as a study to determine...
23:56 , Aug 2, 2017 |  BC Extra  |  Company News

Management tracks: Grail, Foresee, Applied Genetic Technologies

Cancer company Grail Inc. (Menlo Park, Calif.) named Chairman Bill Rastetter as CEO. The company also promoted Ken Drazen to president from CBO. Drug delivery company Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) named Lawrence Gan CEO....
18:32 , Mar 8, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Viral vectors; gene therapy A Cas9 ortholog derived from Campylobacter jejuni could enable the use of AAV vectors to deliver CRISPR-based gene therapies. The 984-residue C. jejuni ortholog is smaller than the Cas9 enzymes...